Manchester, UK. May 20th 2025 – Parkers Pharma has announced the introduction of Spinomax XRT, a 180-day extended-release larvicide tablet formulated with 6.25% Spinosad. The technology offers an evidence-based solution for mosquito control in regions affected by vector-borne diseases such as malaria, dengue, Zika virus, chikungunya, and Rift Valley fever.
Spinomax XRT has been developed under the leadership of scientist Dr. Wathek Zair, and represents a significant milestone in larval source management, particularly in settings where routine application is not feasible due to limited resources or logistical constraints.
Scientific Basis and Mode of Action
Spinosad, the active ingredient in Spinomax XRT, is a naturally derived compound sourced from Saccharopolyspora spinosa. It targets mosquito larvae by disrupting nicotinic acetylcholine receptors, leading to paralysis and death within hours of exposure. The extended-release matrix allows the active ingredient to maintain effective concentrations for up to six months, supporting sustained vector control in aquatic breeding sites.
Application and Efficacy
Spinomax XRT is suitable for use in a variety of breeding environments, including:
• Water tanks and containers
• Agricultural runoff zones
• Urban construction areas
• Flood-prone fields and wetlands
• Refugee camps and temporary settlements
According to preliminary field data and laboratory studies, the product begins to act within 4–24 hours of deployment. It has demonstrated broad-spectrum efficacy against Anopheles, Aedes, and Culex species— primary vectors of global vector-borne diseases. To date, no resistance to Spinosad has been reported in target mosquito populations.
Expert Perspective.
“Spinomax XRT is one of the most promising larvicides we’ve tested. Its long-term release and rapid action allow us to prevent mosquito emergence in areas where daily treatment isn’t feasible. This is a major step forward in vector control.” — Dr. Emma Caldwell, Senior Vector Biologist, Centre for Tropical Disease Control, UK Regulatory Pathway and Global Reach.
Spinomax XRT is undergoing regulatory submission and review in multiple endemic countries across Africa, Asia, and Latin America. The formulation aligns with the World Health Organization’s recommendations for larval source management as a supplementary vector control method, particularly in areas with resistance to adulticide sprays or logistical challenges.
Commitment to Public Health Innovation
“This development reflects our commitment to deliver practical, science-driven tools for global disease control,” said Dr. Wathek Zair, scientist at Parkers Pharma. “By extending the duration of larvicide effectiveness, we’re addressing a critical gap in current vector control strategies.”